Abstract
2061 Background: Limited treatment options exist for patients with recurrent Malignant Gliomas (MG), especially after failing Bevacizumab (BEV). Signal transduction pathways involved in gliomagenes...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
